Abstract:The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an evolving DNA-sensing mechanism involved in innate immunity and pathogen defense that has been optimized while remaining conserved. Aside from recognizing pathogens through conserved motifs, these receptors also detect aberrant or misplaced self-molecules as possible signs of perturbed homeostasis. Upon binding external or self-derived DNA, a mobile secondary messenger 2′3′-cyclic GMP-AMP (cGAMP) is produced by cGAS and in turn activates its adapter STING in the endoplasmic reticulum (ER). Resting-state or activated STING protein is finely restricted by multiple degradation machineries. The post-translational changes of the STING protein, along with the regulatory machinery of the secret routes, limit the onset, strength and sustention of STING signal. STING experiences a conformational shift and relocates with TBK1 from the ER to perinuclear vesicles containing transcription factors, provoking the transcription activity of IRF3/IFN-I and NF-κB pathways, as well as to initiate a number of cellular processes that have been shown to alter the immune landscape in cancer, such as autophagy, NLRP3 inflammasome, ER stress, and cell death. STING signal thus serves as a potent activator for immune mobilization yet also triggers immune-mediated pathology in tissues. Recent advances have established the vital role of STING in immune surveillance as well as tumorigenic process. This review provides an overview of the disparate outcomes of cancer attributed to the actions of pleiotropic and coordinated STING downstream signalosomes, along with the underlying mechanisms of STING function in pathologies, providing therapeutic implications for new approaches in hunt for the next generation of cancer immunotherapy base on STING.

The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING–IFN-β pathway

Protein Kinase STK24 Promotes Tumor Immune Evasion Via the AKT‐PD‐L1 Axis

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Death-associated protein kinase 3 modulates migration and invasion of triple-negative breast cancer cells

Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer.

STAT3 Inhibition Enhances CDN-induced STING Signaling and Antitumor Immunity

Γδ T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-β Signaling Pathways.

TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections

Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis

Tumor-Derived cGAMP Regulates Activation of the Vasculature

DNA sensing via STING regulates autoimmunity and tumor immunity. (IRM5P.648)

PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment

The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance

NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis

TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity

Advances in the Prerequisite and Consequence of STING Downstream Signalosomes

An Analysis of the Expression and Association with Immune Cell Infiltration of the Cgas/sting Pathway in Pan-Cancer

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment

Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: How therapy can overcome them